Governments endorse greater protections for sharks amid concerns about overfishing

At the CITES conference in Uzbekistan, governments approved greater protections for more than 70 shark and ray species, including trade bans on oceanic whitetip sharks, manta and devil rays and whale sharks, strengthened traceability and legal/source requirements for gulper, smoothhound and tope sharks, and zero annual export quotas for several guitarfishes and wedgefishes. Conservationists framed the move as targeting a roughly $1 billion international trade amid concerns that more than 37% of shark and ray species are threatened and over 100 million are killed annually; the measures are regulatory and conservation-focused and are likely to have limited direct market impact beyond potential compliance and trade effects for fisheries exporters and related supply chains.

Analysis

Market structure: The CITES-driven bans shift pricing power toward non-shark substitutes and vertically integrated aquaculture suppliers. Expect synthetic/plant-based squalane producers (Amyris AMRS, Croda CRDA.L) to capture additional share and see spot/APR price pressure relief for mainstream fish oils, with a plausible 10–30% repricing in specialized shark-derivative inputs over 6–12 months as legal supply tightens.

Risk assessment: Tail outcomes range from strong enforcement creating a multi-month supply shock in niche inputs (high-impact, low-probability) to weak enforcement leaving markets unchanged; immediate effects should be limited, material moves are likely over 3–18 months as exporters retool and traceability rules bite. Hidden dependencies include bycatch regulation, national export controls and NGO-led consumer campaigns that can amplify effects; key catalysts are national implementation deadlines, EU/US import rule changes, and marketplace delistings.

Trade implications: Tactical, concentrated exposure to synthetic squalane leaders and large sustainable aquaculture names offers asymmetric upside if substitution accelerates. Option structures (12–18 month call spreads) limit downside while capturing adoption; avoid broad short positions in seafood ETFs—dislocation is niche and could rebound if substitutes lag.

Contrarian angles: Consensus may overstate macro impact on global seafood—shark derivatives are a small share of total marine commodity value, so broad sector sell-offs would be overdone. The real mispricing is in specialty-ingredient makers with scalable biosynthesis (AMRS, CRDA) where market underestimates regulatory-driven demand switching; unintended consequence: higher black‑market premiums for banned products, raising enforcement risk for small exporters.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Amyris (AMRS) over 6–12 months via a bullish call-spread: buy 12–15 month LEAPS ATM calls and sell a higher strike 12–15 month call to cap cost (target +40% upside, stop-loss -25%).
• Add a 1–2% position in Croda (CRDA.L) (or ADR equivalent) for 9–18 months to capture plant-based squalane adoption; set a 20–30% upside target and a 20% hard stop.
• Initiate a 1% long position in Mowi ASA (MOWI.OL) as a defensive seafood/aquaculture play to absorb substitution demand within 3–12 months; trim if salmon spreads compress by >15% or if regulatory headwinds emerge.
• Buy a limited-cost directional: 12-month AMRS call spread sized to 1% of portfolio (e.g., buy 2026 Jan 15C, sell 2026 Jan 35C) to capture adoption with capped downside and close if AMRS moves >50% or if CITES enforcement signals fade within 90 days.
• Reduce direct EM small-cap exposure to coastal fisheries (reduce position sizes by ~50% within 30 days) in portfolios with Indonesia/SE Asia fisheries exposure; redeploy into the above names or cash until national implementation rules (monitor WTO/CITES national listings) are clarified (watch 30–180 day implementation windows).